Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd has announced the publication of results for its next-generation PromarkerD test system in The Journal of Applied Laboratory Medicine. The test, which predicts diabetes-related chronic kidney disease (DKD) up to four years before symptoms appear, demonstrated excellent predictive performance and accuracy, outperforming current standard tests. This advancement is expected to significantly impact diabetes management by enabling earlier intervention and reducing healthcare costs, with the test now available in Australia and the USA for Type-2 diabetes patients.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a leader in precision diagnostics, focusing on the development of innovative diagnostic tests. The company is known for its work in predictive diagnostics, particularly in the healthcare sector, and aims to improve patient outcomes through advanced medical testing solutions.
Average Trading Volume: 320,928
Technical Sentiment Signal: Sell
Current Market Cap: A$71.2M
For an in-depth examination of PIQ stock, go to TipRanks’ Overview page.